Eton Pharmaceuticals Inc. (ETON)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Eton Pharmaceuticals, Inc. (ETON) Q1 2026 Earnings Call Transcript
Eton Pharmaceuticals, Inc. (ETON) Q1 2026 Earnings Call Transcript
Eton Pharmaceuticals Q1 Earnings Call Highlights
Eton Pharmaceuticals NASDAQ: ETON raised its 2026 revenue outlook after reporting record first-quarter product sales and highlighting early progress from two recent product launches, DESMODA and HEMANGEOL.
Eton Pharmaceuticals, Inc. (ETON) Misses Q1 Earnings Estimates
Eton Pharmaceuticals, Inc. (ETON) came out with quarterly earnings of $0.05 per share, missing the Zacks Consensus Estimate of $0.1 per share. This compares to earnings of $0.07 per share a year ago.
Eton Pharmaceuticals (ETON) Surges 19.8%: Is This an Indication of Further Gains?
Eton Pharmaceuticals (ETON) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Eton Pharmaceuticals (ETON) Soars 6.7%: Is Further Upside Left in the Stock?
Eton Pharmaceuticals (ETON) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Recent Price Trend in Eton Pharmaceuticals (ETON) is Your Friend, Here's Why
Eton Pharmaceuticals (ETON) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Does Eton Pharmaceuticals (ETON) Have the Potential to Rally 49.25% as Wall Street Analysts Expect?
The mean of analysts' price targets for Eton Pharmaceuticals (ETON) points to a 49.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Eton Pharmaceuticals, Inc. (ETON) Q4 Earnings Lag Estimates
Eton Pharmaceuticals, Inc. (ETON) came out with quarterly earnings of $0.05 per share, missing the Zacks Consensus Estimate of $0.12 per share. This compares to a loss of $0.02 per share a year ago.
Eton Pharmaceuticals: An Undervalued Small Cap With High Growth
Eton offers a diversified, acquisition-driven portfolio in ultra-rare pediatric endocrinology and metabolic diseases, targeting significant peak sales potential. My DCF-based Fair Value is $28.1, representing 85% upside; optimistic scenarios suggest up to $40 per share, while downside risk is mitigated by product diversification. Revenue growth, free cash flow positivity, and declining SG&A margins support a Buy-to-Strong Buy stance at $15.17, despite high uncertainty from US drug pricing.
Eton Pharmaceuticals, Inc. (ETON) Reports Q3 Loss, Beats Revenue Estimates
Eton Pharmaceuticals, Inc. (ETON) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of $0.13. This compares to earnings of $0.02 per share a year ago.
Eton Pharmaceuticals, Inc. (ETON) Q2 2025 Earnings Call Transcript
Eton Pharmaceuticals, Inc. (NASDAQ:ETON ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants David C. Krempa - Chief Business Officer James R.
Eton Pharmaceuticals: Growth At A Reasonable Price, Or Maybe Even Better With Options
Eton Pharmaceuticals offers GARP potential, focusing on ultra-rare disease drugs acquired at low cost, with a lean, specialized sales force and positive cash flow. My DCF model shows 80%-87% upside to fair value ($26.17) in the base case, with even higher potential in optimistic scenarios. Risks include pipeline failures and US drug price pressures, but even pessimistic scenarios suggest current valuation is fair, limiting downside.
